Search
Search Results
-
Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation
PurposeFactor Xa Inhibitors have emerged as a first-line agent in the management of non-valvular atrial fibrillation (NVAF), but there is a need for...
-
Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors
The regimens for factor Xa (FXa) inhibitors (apixaban, edoxaban, and rivaroxaban) vary with venous thromboembolism (VTE) or non-valvular atrial...
-
Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage
Andexanet alfa (AA) is a recombinant factor Xa competing for binding with factor Xa inhibitors, thereby reversing their anticoagulation effects....
-
Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study
BackgroundUnfractionated heparin (UFH) is primarily monitored using activated partial thromboplastin time (APTT). However, the recent introduction of...
-
The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases
It is unclear which factor Xa (FXa) inhibitors are associated with higher bleeding risk in patients with respiratory diseases, and there are no...
-
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
Oral factor Xa (FXa) inhibitors significantly reduce incidence of stroke and thromboembolic events in patients with atrial fibrillation or venous...
-
Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds
Given the paucity of comparative efficacy data and the difference in cost between andexanet-alfa and prothrombin complex concentrates (PCC), debates...
-
A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19
BackgroundPatients with critical COVID-19 have a high risk of thromboembolism, but intensified thromboprophylaxis has not been proven beneficial. The...
-
QSAR and Molecular Modeling Studiesof Factor Xa and Thrombin Inhibitors
Thrombotic disorders remain the major cause of death and disability in Western society. Many approaches to develop antithrombotic drugs that...
-
Lysyl oxidase-like 2 processing by factor Xa modulates its activity and substrate preference
Lysyl oxidase-like 2 (LOXL2) has been identified as an essential mediator of extracellular matrix (ECM) remodeling in several disease processes...
-
Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries
BackgroundAnticoagulant use prior to trauma has been associated with increased incidence of traumatic brain injury (TBI), intracranial hemorrhage...
-
An In-Depth Review of Reversing Direct Factor XA-Inhibitor-Related Hemorrhages
This chapter focuses on the reversal strategies for Direct Factor-Xa inhibitors. Adnexanet alfa is now FDA approved, but not widely available given...
-
Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
Low-molecular-weight heparin (LMWH) is an anticoagulant used to prevent clotting during blood purification treatments. This study aimed to evaluate...
-
An Overview of Heparin Monitoring with the Anti-Xa Assay
Heparin remains a critical therapy in hospitalized patients requiring anticoagulation. Unfractionated heparin (UFH) mediates its therapeutic effect...
-
Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation
BackgroundChromogenic anti-factor Xa activity (AXA) assay is used to measure the pharmacodynamics of factor Xa inhibitors, including edoxaban....
-
Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection
Serine proteases (SP), including furin, trypsin, and TMPRSS2 cleave the SARS-CoV-2 spike (S) protein, enabling the virus to enter cells. Here, we...
-
Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
IntroductionGuidelines have endorsed non-vitamin K antagonist oral anticoagulants (NOACs), consisting of factor Xa inhibitors (xabans) and direct...
-
Do Oral Factor Xa Inhibitors have a Role in Patients with Mechanical Heart Valves?
Mechanical heart valves (MHVs) replacement is recommended for younger patients with valvular heart disease because of the durability of the...
-
Platelet-rich fibrin ensures hemostasis after single-tooth removal under factor Xa inhibitors — a clinical prospective randomized split-mouth study
ObjectivesIn this prospective, double-blinded, randomized split-mouth study, the local hemostatic effect of platelet-rich fibrin (PRF) inserted into...
